Intended Use

The Liverscan C is intended to provide shear wave speed measurements and estimates of tissue stiffness as well as ultrasound coefficient of attenuation (MAP) in internal structures of the body, for aiding clinical management and diagnosis of adult patients with liver disease.

Technology

The device uses a 3.5 MHz piezoelectric ultrasound transducer and shear wave elastography techniques to measure shear wave speed and stiffness, along with ultrasound attenuation via the Mobile Attenuation Parameter (MAP). It operates on Windows 10 Embedded OS and features B-mode and transient elastography imaging modes.

Performance

The device underwent non-clinical bench testing for electrical safety, electromagnetic compatibility, usability, software verification, and performance testing per IEC and ISO standards, demonstrating substantial equivalence to the predicate device. No clinical testing was conducted.

Predicate Devices

No predicate devices specified

Device Timeline

  • 1

    Submission

    8/22/2024

    2 months
  • 2

    FDA Approval

    11/19/2024

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.